Outlook Therapeutics (OTLK) Income from Non-Controlling Interests (2015)
Outlook Therapeutics (OTLK) posted quarterly Income from Non-Controlling Interests of -$896136.0 for Q3 2015, down 135.56% quarter-over-quarter from -$380435.0 in Q2 2015.
Outlook Therapeutics (OTLK) Income from Non-Controlling Interests (2015) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Income from Non-Controlling Interests for 1 consecutive years, with -$896136.0 the latest figure, recorded in Q3 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | -896,136.00 |
| Jun 30, 2015 | -380,435.00 |